Sector News

Pfizer could buy GSK, but would Shire or Perrigo offer better targets?

May 22, 2015
Life sciences
The speculation is building this week that Pfizer will either attempt another megadeal with GlaxoSmithKline or another run on AstraZeneca. Either would cut Pfizer’s tax rate and give it some products to salve its various ills, lackluster stock price and poor performing portfolio. But the new thinking, like in the last 24 hours, is that smaller deals, perhaps a buyout of Shire or even Perrigo, or both, are better bets. 
 
Jefferies Group analyst Jeffrey Holford, likes that scenario. Bloomberg reports that in a note to investors, Holford mentioned both Shire and Perrigo as potentially attractive to the pharma giant. Both have Ireland corporate addresses, meaning Pfizer, through an inversion, could cut its tax costs. Both have portfolios that could be of interest to Pfizer as it looks for deals that could bolster different pieces of its business in preparation for the big breakup that many investors are hoping for. 
 
“We believe that other significant acquisitions are possible,” Holford wrote Thursday in a note to investors. As Holford sees it, Pfizer can mine “a rich seam of corporate optionality.”
 
Of course, Perrigo, whose business is weighted toward over-the-counter products, is already being hotly pursued by Mylan, which in turn is facing a takeover attempt by generics giant Teva. Mylan’s executive chairman has suggested Pfizer could just buy it after it swallows Perrigo.
 
Perrigo has rejected three offers from Mylan although its CEO Joseph Papa indicated this week it would be more amiable if the price is right. Of course, that kind of talk could also be a signal that he is looking for someone else, perhaps someone with deeper pockets to join the bidding. Could that someone be Pfizer?
 
Pfizer CEO Ian Read has not shown his cards in this, only offering tidbits that suggest his thinking. Even though the U.S. Treasury has made some tax changes that discourage the kinds of tax inversions any of these deals present, Read has said he doesn’t see those as keeping that kind of deal from happening.
 
A run at GSK could potentially come with the same kind of British backlash that defeated Pfizer in its $100 billion-plus deal for AstraZeneca. Still, Deutsche Bank made a case this week for the effort. They see it providing not only tax benefits to lower costs, but a punch to Pfizer’s earnings, along with the kind of short-term kick that can flow from finally achieving a big M&A deal. And as Deutsche Bank’s Gregg Gilbert see its, the clock is ticking for Pfizer. Bloomberg reported that in a note, the analyst told investors he thinks Pfizer is feeling “a sense of urgency” to use its substantial balance sheet “to do needle-moving deals.” 
 
By Eric Palmer
 

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.